एटाज़ानाविर और डारुनाविर का इंटरैक्शन

Others ↑ other protease inhibitor Coadministration with other protease inhibitors is not recommended.

Resistance to atazanavir may not preclude the subsequent use of other protease inhibitors [see Microbiology (12.4) ] .

Potential for REYATAZ to Affect Other Drugs Atazanavir is an inhibitor of CYP3A and UGT1A1.

Co-administration of darunavir and ritonavir and other drugs that inhibit CYP3A, or P-gp may decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of darunavir and ritonavir (see Table 10 ).

Other HIV protease inhibitors, except atazanavir [see Drug Interactions (7.4) ] As co-administration with PREZISTA/ritonavir has not been studied, co-administration is not recommended.

Drugs without Clinically Significant Interactions with PREZISTA No dosage adjustments are recommended when PREZISTA/ritonavir is co-administered with the following medications: atazanavir, dolutegravir, efavirenz, etravirine, nevirapine, nucleoside reverse transcriptase inhibitors (abacavir, emtricitabine, emtricitabine/tenofovir alafenamide, lamivudine, stavudine,…